Full text loading...
薬理と治療
- Authors: Yuko Akasaka1, Akira Hatta1, Toshitsugu Sato1, Jost Leuschner2, Chieko Sasagawa1, Hideo Inoue1
Abstract
Single dose toxicity of monoammonium glycyrrhizinate, used for the therapy of hepaticdiseases as well as allergic diseases, was investigated using CD−1 mice and CD rats. Thedose levels of dosage were 215, 316 and 464 mg/kg for mice, and were 316, 464 and 681 mg/kg for rats. Each experimental group consisted of 5 male and 5 female animals. No signs oftoxicity were observed in the low dose groups in both species. Treatment with the middledose levels caused the slight or moderate reduction of motility, slight or moderate ataxia,tremor and dyspnoea in more than 4 animals in each sex of both species. Clonic and tonic convulsionsand abdominal position were noted in 2 males and 1 male, respectively, in ratexperiment. One male and 1 female mice and 2 male rats died. All symptoms were observedwithin 30 and 60 minutes in mouse and rat experiments, respectively. The high dose levelsrevealed moderate dyspnoea, clonic and tonic convulsions, and abdominal position in all mice.Moderately reduced motility, moderate ataxia and dyspnoea, tremor, and salivation wererecorded in all rats. In rat, clonic and tonic convulsions were also observed in 5 males and 1female, and abdominal position was revealed in 1 female. In high dose treatment, all animalsdied within 60(mice)and 30(rats)minutes. The LD50 values(24 hours and 14 days)ofmice and rats were 325 mg/kg and 478 mg/kg, respectively.(Jpn Pharmacol Ther 2008;36:1017−23)KEY WORDS Glycyrrhizin, Acute toxicity, Single intravenous administration, Rodent, LD50
Data & Media loading...